CD26/dipeptidyl peptidase IV and its role in cancer

Histology and Histopathology

Volumn 19, Issue 4, 2004, Pages 1345-1351

  Pro, B ^a   Dang, Nam H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; CD26 DPPIV; Chemokines; T cell lymphoid malignancies; Targeted therapy

Indexed keywords

CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; GLYCOPROTEIN; GROWTH FACTOR; NEUROPEPTIDE; PEPTIDE; PROLINE;

APOPTOSIS; CARCINOGENESIS; CELL TYPE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; IMMUNOREGULATION; MOLECULAR INTERACTION; MOLECULAR SIZE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTIGENS, CD26; HUMANS; LYMPHOMA, T-CELL; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 6344253102     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Abdel-Ghany M., Cheng H., Levine R.A. and Pauli B.U. (1998). Truncated dipeptidyl pepticlase IV is a potent anti-adhesion and anti-metastasis peptide for rat breast cancer cells. Invasion Metast. 18, 35-43.
2. Aratake Y., Kotani T., Tamura K., Araki Y., Kuribayashi T., Konoe K. and Ohtaki S. (1991). Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases. Am. J. Clin. Pathol. 96, 306-310.
3. Asada Y., Aratake Y., Kotani T., Marutsuka K., Araki Y., Ohtaki S. and Sumiyoshi A. (1993). Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma. Histopathology 23, 265-270.
4. Aytac U., Claret F.-X., Ho L., Sato K., Ohnuma K., Mills G.B., Cabanillas F., Morimoto C. and Dang N.H. (2001). Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the C2/M checkpoint. Cancer Res. 61, 7204-7210.
5. Aytac U., Sato K., Yamochi T., Yamochi T., Ohnuma K., Mills G.B., Morimoto C. and Dang N.H. (2003). Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors. Br. J. Cancer 88, 455-462.
6. Bauvois B. (1988). A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. Biochem. J. 252, 723-731.
7. Bauvois B., De Meester I., Dumont J., Rouillard D., Zhao HX and Bosmans E. (1999). Constitutive expression of CD26dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. Br. J. Cancer 79, 1042-1048.
8. Bernengo M.G., Novelli M., Quaglino P., Lisa F., De Matteis A., Savoia P., Cappello N. and Fierro M.T. (2001). The relevance of the CD4+ CD26- subset in the identification of circulating Sezary cells. Br. J. Dermatol. 144, 125-135.
9. Carbone A., Cozzi M., Gloghini A. and Pinto A. (1994). CD26/dipeptidylpeptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas. Human Pathol. 25, 1360-1365.
10. Carbone A., Gloghini A., Zagonel V., Aldinucci D., Gattei V., Degan M., Improta S., Sorio R., Monfardini S. and Pinto A. (1995). The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 86, 4617-4626.
11. Cheng H.C., Abdel-Ghany M., Elble R.C. and Pauli B.U. (1998). Lung endothelial clipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem. 273, 24207-24215.
12. Cheng H.C., Abdel-Ghany M. and Pauli B.U. (2003). A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J. Biol. Chem. 278, 24600-24607.
13. Christopherson K.W., Cooper S. and Broxmeyer H.E. (2003a). Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 101, 4680-4686.
14. Chistopherson K.W., Cooper S., Hangoc G. and Broxmeyer H.E. (2003b). CD26 isessential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp. Hematol. 31, 1126-1134.
15. Cordero O.J., Ayude D., Nogueira M., Rodriguez-Berrocal F.J., and de la Cadena M.P. (2000). Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br. J. Cancer 83, 1139-1146.
16. Dang N.H., Hagemeister F.B., Duvic M., Romaguera J.E., Younes A., Jones D., Samuels B., Fayad L.E., Pro B., Samaniego F., Sarris A., Goy A., McLaughlin P., Tong A.T., Walker P.L., Tiongson L.P., Smith T.L., Huh Y.O., Morimoto C. and Rodriguez M.A. (2003a). Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol. Rep. 10, 1513-1518.
17. Dang N.H., Aytac U., Sato K., O'Brien S., Melenhorst J., Morimoto C., Barrett A.J. and Molldrem J.J. (2003b). T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br. J. Haematol. 121, 857-865.
18. Dang N.H., Hafler D.A., Schlossman S.F. and Breitmeyer J.B. (1990a). FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation. Cell Immunol. 125, 42-57.
19. Dang N.H., Torimoto Y., Deusch K., Schlossman S.F. and Morimoto C. (1990b). Comitogenic effect of solid-phase immobilized anti-1 F7 on human CD4 T cell activation via CD3 and CD2 pathways. J. Immunol. 144, 4092-4100.
20. Dang N.H., Torimoto Y., Sugita K., Daley J.F., Schow P., Prado C., Schlossman S.F. and Morimoto C. (1990c). Cell surface modulation of CD26 by anti-1 F7 monclonal antibody: analysis of surface expression and human T cell activation. J. Immunol. 145, 3963-3971.
21. Dang N.H., Torimoto Y., Schlossman S.F. and Morimoto C. (1990d). Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1 F7 and VLA integrin family. J. Exp. Med. 172, 649-652.
22. Dang N.H., Torimoto Y., Shimamura K., Tanaka T., Daley J.F., Schlossman S.F. and Morimoto C. (1991). 1 F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J. Immunol. 147, 2825-32.
23. Dong R.P., Kameoka J., Hegen M., Tanaka T., Xu Y., Schlossman S.F. and Morimoto C. (1996). Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J. Immunol. 156, 1349-1355.
24. Dong R.P., Tachibana K., Hegen M., Munakata Y., Cho D., Schlossman S.F. and Morimoto C. (1997). Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J. Immunol. 159, 6070-6076.
25. Hirai K., Kotani T., Aratake Y., Ohtaki S. and Kuma K. (1999). Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor. Pathol. Int. 49, 264-265.
26. Ho L., Aytac U., Stephens L.C., Ohnuma K., Mills G.B., McKee K.S., Neumann C., LaPushin R., Cabanillas F., Abbruzzese J.L., Morimoto C. and Dang N.H. (2001). In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin. Cancer Res.7, 2031-2040.
27. Houghton A.N., Albino A.P., Cordon-Cardo C., Davis L.J. and Eisinger M. (1988). Cell surface antigens of human melanocytes and melanoma-expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J. Exp. Med. 167, 197-212.
28. Ikushima H., Munakata Y., Ishii T., Iwata S., Terashima M., Tanaka H., Schlossman S.F. and Morimoto C. (2000). Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. Proc. Natl. Acad. Sci. USA 97, 8439-8444.
29. Ikushima H., Munakata Y., Iwata S., Ohnuma K., Kobayashi S., Dang N.H. and Morimoto C. (2002). Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol. 215, 106-110.
30. Ishii T., Ohnuma K., Marakami A., Takasawa. N., Kobayashi S., Dang N.H., Schlossman S.F. and Morimoto C. (2001). CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc. Natl. Acad. Sci. USA 98, 12138-12143.
31. Jones D., Dang N.H., Duvic M., Washington L.T. and Huh Y.O. (2001). Absence of CE26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am. J. Clin. Pathol. 115, 885-892.
32. Kajiyama H., Kikkawa F., Suzuki T., Shibata K., Ino K. and Mizutani S. (2002). Prolonged survival and decreased invasive activity attributes to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res. 62, 2753-2757.
33. Kajiyama H., Kikkawa F., Khin E., Shibata K., Ino K. and Mizutani S. (2003). Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res. 63, 2278-2283.
34. Kameoka J., Tanaka T., Nojima Y., Schlossman S.F. and Morimoto C. (1993). Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261, 466-469.
35. Khin E.E., Kikkawa F., Ino K., Kajiyama H., Suzuki T., Shibata K., Tamakoshi K., Nagasaka T. and Mizutani S. (2003). Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. Am J Obstet Gynecol. 188, 670-676.
36. Klobusicka M. and Babusikova O. (1999). Expression of CD26 and DPP IV in T-acute lymphoblastic leukemia: comparison of immunocytochemistry with enzyme cytochemistry. Neoplasma 46, 299-303.
37. Kobayashi S., Ohnuma K., Uchiyama M., Iino K., Iwata S., Dang N.H. and Morimoto C. (2004). Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation. Blood 103, 1002-1010.
38. Kotani T., Aratake Y., Ogata Y., Umeki K., Araki Y., Hirai K., Kuma K. and Ohtaki S. (1991). Expression of dipeptidyl aminopeptidase IV activity in thyroid carcinoma. Cancer Lett. 57, 203-208.
39. Kotani T., Asada Y., Aratake Y., Umeki K., Yamamoto I., Tokudome R., Hirai K., Kuma K., Konoe K. and Araki Y. (1992a). Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours. J. Pathol. 168, 41-45.
40. Kotani T., Kawano J., Suganuma T., Hirai K., Umeki K., Aratake Y., Konoe K. and Ohtaki S. (1992b). Immunohistochemical localization of dipeptidyl aminopeptidase IV in thyroid papillary carcinoma. Int. J. Exp. Pathol. 73, 215-222.
41. Loster K., Zeilinger K., Schuppan D. and Reutter W. (1995). The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem. Biophys. Res. Commun. 217, 341-338.
42. Masuyama J., Berman J.S., Cruikshank W.W., Morimoto C. and Center D.M. (1992). Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J. Immunol. 148, 1367-1374.
43. Morimoto C., Torimoto Y., Levinson G., Rudd C.E., Schrieber M., Dang N.H., Letvin N.L. and Schlossman S.F. (1989). 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J. Immunol. 143, 3430-3439.
44. Morrison M.E., Vijayasaradhi S., Engelstein D., Albino A.P. and Houghton A.N. (1993). A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J. Exp. Med. 177, 1135-1143.
45. Ohnuma K., Munakata Y., Ishii T., Iwata S., Kobayashi S., Hosono O., Kawasaki H., Dang N.H. and Morimoto C. (2001). Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J. Immunol. 167, 6745-6755.
46. Pethiyagoda C.L., Welch D.R. and Fleming T.P. (2001). Dipeptidy] peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin. Exp. Metast 18, 391-400.
47. Piazza G.A., Callanan H.M., Mowery J. and Hixson D.C. (1989). Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem. J. 262, 327-334.
48. Proost P., De Meester I., Schols D., Struyf S., Lambeir A.-M., Wuyts A., Opdenakker G., De Clercq E., Scharpe S. and Van Damme J. (1998). Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV: conversion of RANTES into a potent inhibitor of monocyte chernotaxis and HIV-1 -infection. J. Biol. Chem. 273, 7222-7227.
49. Proost P., Struyf S., Schols D., Opdenakker G., Sozzani S., Allavena P., Mantovani A., Augustyns K., Bal G., Haemers A., Lambeir A.-M., Scharpe S., Van Damme J. and De Meester I. (1999). Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J. Biol. Chem. 274, 3988-3993.
50. Ruiz P., Mailhot S., Delgado P., Amador A., Viciana A.L., Ferrer L. and Zacharievich N. (1998). CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma. Cytometry 34, 30-35.
51. Sato K. and Dang N.H. (2003). CD26: a novel treatment target for T-cell lymphoid malignancies? (Review). Int. J. Oncol. 22, 481-497.
52. Sato K., Aytac U., Yamochi T., Yamochi T., Ohnuma K., McKee K.S., Morimoto C. and Dang N.H. (2003). CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors. Br. J. Cancer 89, 1366-1374.
53. Stecca B.A., Nardo B., Chieco P., Mazziotti A., Bolondi L. and Cavallari A. (1997). Aberrant dipeptidyl peptidase IV (DPPIV/CD26) expression in human hepatocellular carcinoma. J. Hepatol. 27, 337-345.
54. Tanaka T., Camerini D., Seed B., Torimoto Y., Dang N.H., Kameoka J., Dahlberg H.N., Schlossman S.F. and Morimoto C. (1992). Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 149,481-486.
55. Tanaka T., Kameoka J., Yaron A., Schlossman S.F. and Morimoto C. (1993). The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Sci. USA 90, 4586-4590.
56. Tanaka T., Umeki K., Yamamoto L, Sakamoto F., Noguchi S. and Ohtaki S. (1995). CD26 (dipeptidyl peptidase IV/DPPIV) as a novel molecular marker for differentiated thyroid carcinoma. Int. J. Cancer 64, 326-331.
57. Torimoto Y., Dang N.H., Tanaka T., Prado C., Schlossman S.F. and Morimoto C. (1992). Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Mol. Immunol. 29, 183-192.
58. Torimoto Y,, Dang N.H., Vivier E., Tanaka T., Schlossman S.F. and Morimoto C. (1991). Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J. Immunol. 147, 2514-2517.
59. Uematsu T., Urade M. and Yamaoka M. (1998). Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients. J. Oral Pathol. Med. 27, 106-110.
60. Uematsu T., Urade M., Yamaoka M. and Yoshioka W. (1996). Reduced expression of dipeptidyl peptidase (DDP) IV in peripheral blood T lymphocytes of oral cancer patients. J. Oral Pathol. Med. 25, 507-512.
61. Wesley U.V., Albino A.P., Tiwari S. and Houghton A.N. (1999). A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J. Exp. Med. 190, 311-322.
62. Wesley U.V., Tiwari S. and Houghton A.N. (2004). Role of dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int. J. Cancer 109, 855-66.
63. Wilson M.J., Ruhland A.R., Quast B.J., Reddy P.K., Ewing S.L. and Sinha A.A. (2000). Dipeptidyl IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. J. Androl. 21, 220-226.